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Abstract
Inherited retinal degenerations, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), represent
leading causes of incurable blindness in humans. This is also true in dogs, where the term progressive retinal atrophy (PRA) is
used to describe inherited photoreceptor degeneration resulting in progressive vision loss. Because of the similarities in
ocular anatomy, including the presence of a cone photoreceptor-rich central retinal region, and the close genotype-
phenotype correlation, canine models contribute significantly to the understanding of retinal disease mechanisms and the
development of new therapies. The screening of the pure-bred dog population for new forms of PRA represents an
important strategy to establish new large animal models. By examining 324 dogs of the Swedish vallhund breed in seven
countries and across three continents, we were able to describe a new and unique form of PRA characterized by the
multifocal appearance of red and brown discoloration of the tapetal fundus followed over time by thinning of the retina. We
propose three stages of the disease based on the appearance of the ocular fundus and associated visual deficits.
Electroretinography revealed a gradual loss of both rod and cone photoreceptor-mediated function in Stages 2 and 3 of the
disease. In the few dogs that suffered from pronounced vision loss, night-blindness occurred first in late Stage 2, followed by
decreased day-vision in Stage 3. Histologic examinations confirmed the loss of photoreceptor cells at Stage 3, which was
associated with the accumulation of autofluorescent material in the adjacent retinal pigment epithelium. Pedigree analysis
was suggestive of an autosomal-recessive mode of inheritance. Mutations in six known canine retinal degeneration genes as
well as hypovitaminosis E were excluded as causes of the disease. The observed variability in the age of disease onset and
rate of progression suggest the presence of genetic and/or environmental disease modifiers.
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Introduction
Inherited retinal diseases are among the leading causes for
incurable vision loss in the human and canine populations [1–5].
In dogs, most of these conditions are classified as progressive
retinal atrophy (PRA), and, similar to many forms of retinitis
pigmentosa (RP) in human patients, primarily affect rod photo-
receptors leading to initial night-vision loss followed by loss of cone
photoreceptors and subsequent day-blindness [1,3,5]. Cone-rod
dystrophies (crd) and primary cone degeneration (cd) have also
been described in dogs with either combined initial day- and
night-vision loss or exclusive day-blindness [1,5]. Inherited retinal
disease can also result from a primary dysfunction of the retinal
pigment epithelium (RPE) of which RPE65- or BEST1-mutant
dogs are examples [1,5–9]. Because of the similarities in ocular
anatomy, including the presence of a cone photoreceptor-rich
central retinal region [10,11], and the frequently similar genotype-
phenotype correlation [1], canine retinal disease models contribute
significantly to our understanding of retinal disease mechanisms
and the development of new therapies for human patients [12–20].
Screening of the pure-bred dog population for new forms of PRA
represents an important strategy to maintain breed health and to
establish new large animal models.
Beginning in the late 1990s, Swedish and Finnish eye panelists
recognized the emergence of a new retinal disease in Swedish
vallhund dogs (Fig. 1). The morphologic retinal abnormalities
seen by indirect ophthalmoscopy were different from any known
forms of canine inherited retinopathy described to date (Finnish
Kennel Club: http://jalostus.kennelliitto.fi/frmEtusivu.aspx;
Swedish Kennel Club: http://kennet.skk.se/avelsdata/). With
the gradual increase of the breed’s international popularity, this
Swedish vallhund retinopathy was also recognized in other parts of
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the world, including North America [2]. The purpose of this study
was to characterize the phenotype and potential etiology of this
condition in order to provide the basis for elimination of the
disease in the canine population. Our findings are based on the
examination of 324 Swedish vallhund dogs in seven countries and
suggest that the Swedish vallhund retinopathy is a new form of
PRA. An autosomal recessive mode of inheritance is most likely.
Materials and Methods
Ethics Statement
All of the described work was conducted in compliance with the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Approval from the local Institutional Animal
Care and Use Committee was obtained when the clinical
examination or sample collection was not part of the services
requested by the dog owner or breeder (County Administrative
Board of Southern Finland ESLH-2009-07827/Ym-23 and
University of Pennsylvania IACUC protocols# 802604 and
803429).
Study Animals
Most of the results described in this study were obtained from
Swedish vallhund dogs clinically examined by the authors (AMK
and PV). The bulk of these dogs resided either in the United States
or Finland, but additional dogs were also examined in Canada and
Sweden. In addition, for pedigree and genetic analyses, Swedish
vallhund dogs examined by other veterinary ophthalmologists or
eye panelists were also included. These latter dogs resided in the
United States, Canada, Finland, Sweden, the United Kingdom,
the Netherlands, and Australia. Although other ocular and
adnexal abnormalities such as persistent pupillary membranes
and cataracts were noted, this study focused exclusively on retinal
lesions.
Clinical Examination
All dogs were examined by hand-held slit-lamp biomicroscopy
(either SL-14, Kowa Company, Tokyo, Japan; or HSO 10, Carl
Zeiss Meditec AG, Jena, Germany) and binocular indirect
ophthalmoscopy (Keeler All Pupil II; Keeler Instruments,
Broomall, PA, USA) with a condensing lens (Pan Retinal 2.2D;
Volk Optical, Mentor, OH, USA) under pharmacologic mydriasis
with topical 1% tropicamide ophthalmic solution. All ocular
abnormalities were documented and, for selected dogs, fundus
photographs were taken with either a portable camera (RC-2,
Kowa Company, Tokyo, Japan) or through a 20-diopter lens
(Volk Optical, Mentor, OH, USA) with a digital video camera
mounted on an indirect ophthalmoscope (Omega 2C, Heine
Optotechnik, Herrsching, Germany). Images were visualized with
Pinnacle studio plus software (Pinnacle, Mountain View, CA,
USA) and individual frames extracted using Vegas Movie Studio
HD Platinum 11.0 (Sony Creative Software, Inc, Middleton, WI,
USA). Additionally, visual performance was assessed by distribu-
tion of a short questionnaire among 40 owners of PRA-affected
Swedish vallhund dogs in Finland. Specifically, we inquired as to
the owner’s perception of the onset and severity of visual deficits
observed in the dogs, such as the ability to see stationary or
moving objects under different light conditions.
Electroretinography
Retinal function was recorded by electroretinography under
general anesthesia in a total of 15 selected Swedish vallhund dogs
in the United States, Sweden and Finland, using the same
equipment and protocol (RETIport, Acrivet, Inc., Salt Lake City,
UT, USA). Premedication by intramuscular injection occurred
with acepromazine maleate (0.5 mg/kg) alone, or a combination
of butorphanol tartrate (0.1–0.2 mg/kg) with either acepromazine
maleate (0.01–0.02 mg/kg) or medetomidine HCl (20 mg/kg).
While one dog was masked with an isoflurane/O2 gas mixture, the
remaining dogs were induced by intravenous injection of propofol
(4–6 mg/kg to effect). All dogs were intubated and inhalation
anesthesia maintained with an isoflurane/O2 gas mixture on a
semiclosed system. The dogs were placed in right lateral
recumbency and left eyes were tested. Central position of the
globe was achieved and maintained by retrobulbar injection of
sterile saline caudal to the orbital ligament (volume to effect). In
order to avoid muscle artifacts in the electroretinogram (ERG), an
auriculopalpebral nerve block was applied by subcutaneous
injection of 2% lidocaine HCl solution along the zygomatic arch.
Two platinum subdermal needle electrodes (Grass Safelead Needle
electrodes, Grass Technologies, West Warwick, RI, USA) were
used: The reference electrode was placed subcutaneously approx-
imately 10 mm from the lateral canthus, and the ground electrode
was placed over the occipital protuberance [21]. A Kooijman/
Damhof ERG corneal contact lens with built-in white LED light
source (Acrivet, Inc.) was used as the active electrode and applied
with 2.5% hypromellose ophthalmic demulcent solution [22].
Following 20 minutes of dark adaptation, a single rod and
maximal rod-cone responses were recorded with a flash intensity
of 0.03 cd.s/m2 (average of 20 sweeps at 0.2 Hz) or 3.0 cd.s/m2
(average of 10 sweeps at 0.06 Hz) respectively. Subsequently, the
eyes were light-adapted to a white uniform background light of
25 cd/m2 from the Kooijman/Damhof ERG contact lens, and
single cone (average of 10 sweeps at 0.5 Hz) and cone flicker
(average of 30 sweeps at 28 Hz) responses were recorded with a
3.0 cd.s/m2 flash intensity. For all recordings, the filters were set to
allow a bandpass of 1 to 300 Hz. For each recording, amplitudes
and implicit times were measured and compared between
individual dogs. The small sample size precluded detailed
statistical analyses.
Histopathology and Immunohistochemistry
Ocular histopathologic examination was performed in eight
Swedish vallhund dogs that were euthanized for unrelated reasons,
and the eyes donated by the owners. Most of the eyes were fixed in
formalin, and routinely processed for paraffin embedding and
hematoxylin and eosin (H&E) staining. For specific examination of
lipopigment accumulation (ceroid/lipofuscin), tissue sections were
stained with acid-fast and counterstained with hematoxylin. One
eye was fixed for 24 h in 4% paraformaldehyde in 0.1 M
phosphate-buffered saline (PBS) at 4uC. Then the anterior
segment and the vitreous were removed, and the tissue was
Figure 1. Appearance of Swedish vallhund dogs. The Swedish
vallhund is a spitz-type herding breed, recognized since the age of the
Vikings (700–1000 A.D.). The breed standard includes erect ears and a
medium-length, hard haircoat. Coat color is a sable pattern in grey, red
or combinations thereof. Tail may be natural (long, stub or bob) or
docked.
doi:10.1371/journal.pone.0106610.g001
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placed sequentially in 15 and 30% sucrose for 24 h each prior to
embedding in optimal cutting temperature (OCT) medium for
cryosectioning. Paraffin sections of normal and PRA-affected eyes
originating from other canine breeds were provided as control
samples by the Anatomic Pathology/Biopsy Service of the
University of Pennsylvania School of Veterinary Medicine and
the Comparative Ocular Pathology Laboratory of Wisconsin
(COPLOW).
To further examine the morphology of cells and the localization
of protein expression within the retina, immunohistochemical
staining of both paraffin and OCT retinal sections was performed
with the following antibodies (Table S1): human cone arrestin (for
cone photoreceptors), rhodopsin (for rod photoreceptors), RPE65
(for the retinal pigment epithelium, RPE), glial fibrillary acidic
protein (GFAP, for astrocytes and Mu¨ller cells), glutamine
synthetase (for Mu¨ller cells) and G0alpha (for ON bipolar cells).
Alexa Fluor-labeled goat anti-rabbit immunoglobulin (IgG) or goat
anti-mouse IgG (Molecular Probes Inc., Eugene, OR, USA) was
used as secondary antibody. 49,6-Diamidino-2-phenylindole
(DAPI) stained the cell nuclei.
Stained tissues were evaluated using light and fluorescent
microscopy with a Zeiss Axioplan microscope (Carl Zeiss Meditec,
Dublin, CA, USA). Images were digitally captured (Spot 4.0
camera; Diagnostic Instruments Inc., Sterling Heights, MI, USA),
and imported into a graphics program (Photoshop; Adobe,
Mountain View, CA, USA) for display. Selected tissues were
imaged by laser scanning confocal microscopy (Olympus Fluo-
View FV1000; Olympus America, Center Valley, PA, USA).
Pedigree and Candidate Gene Analysis
In an attempt to determine genealogical relationships between
as many of the examined Swedish vallhund dogs as possible, a
master pedigree was constructed using GenoPro genealogy
software (http://www.genepro.com/). Genealogical data was
either accessed in public canine registries such as the Finnish
Kennel Club’s Koiranet (http://jalostus.kennelliitto.fi/frmEtusivu.
aspx) or from pedigree information provided by the dog owners.
When the owner’s consent was obtained, either whole blood (in
EDTA-containing tubes) or buccal swabs (Eurotubo Cytobrush,
sterile, 200 mm, Danlab, Helsinki, Finland) were collected for
genomic DNA extraction (QIAmp DNABlood Mini Kit, Qiagen,
Valencia, CA, USA, or Chemagic Magnetic Separation Module I,
Chemagen Biopolymer-Technologie AG, Baeswieler, Germany
for whole blood; or QIAamp DNA Mini Kit, Qiagen for buccal
swabs). DNA concentration was measured using Nanodrop ND-
1000 UV/Vis Spectrophotometer (Nanodrop technologies, Wil-
mington, Delaware, USA); and the DNA was stored at -20uC.
Genes associated with the following forms of inherited canine
retinal diseases were tested for association using fragment analysis
in 11 PRA-affected and 11 unaffected Swedish vallhund dogs:
canine multifocal retinopathy (cmr; gene: BEST1) [8,9], rod-cone
dysplasia type 1 (rcd1; PDE6B) and type 3 (rcd3; PDE6A) [23–
26], progressive rod-cone degeneration (prcd; PRCD) [27], canine
Leber congenital amaurosis (LCA; RPE65) [6,7], cone-rod
dystrophy (crdSWHD, NPHP4) [28], and achromatopsia/cone
degeneration (ACHM/cd; CNGB3) [29,30]. PRA-unaffected dogs
were defined as Swedish Vallhund dogs over the age of six years
who were examined by a board certified veterinary ophthalmol-
ogist and confirmed free of retinal disease.
Primers were designed to amplify two flanking microsatellites
using Primer3 software (http://frodo.wi.mit.edu/primer3/) and
the canine whole genome sequence assembly (CanFam2.0: http://
www.ensembl.org/Canis_familiaris/; see Table S2 for PCR
amplification primers). An 18-bp extension sequence was added
to the 59-end of the forward primers to allow amplification of a
fluorescently labeled third primer Fam-TGACCGGCAG-
CAAAATTG for visualization. Microsatellites were PCR-ampli-
fied using the pooling method: Two pools, one containing DNA
from PRA-affected dogs, and one containing DNA from control
dogs were made, using the exact same amount of DNA (Table
S3). GeneScan LIZ-500 dye size standard (Applied Biosystems by
Life Technologies, Carlsbad, CA, USA) was added to the PCR
products, combined with Hi-Di formamide, and placed onto an
ABI3730xl DNA analyzer (Applied Biosystems). The data was
analyzed using Peak Scanner Software v1.0 (Applied Biosystems)
and compared between the two groups. Possible PCR saturation
was inspected to ensure that none of the amplifications had gone
to completion. As the exact same quantity of DNA was used from
each individual, the fragment sizes were able to be directly
compared between pools. If differences were observed between
case and control pools, individual samples were amplified
separately using the same protocol. Minor differences were
observed between case and control pools for BEST1, CNGB3
and NPHP4 genes, therefore the cases and controls were further
amplified separately for these genes (Table S3). The individual
microsatellite data was then analyzed for the presence of
segregation under a recessive model.
Evaluation of Serum Vitamin E Concentrations and Other
Potential Risk Factors
Because some aspects of the retinal disease phenotype were
remotely reminiscent of vitamin E deficiency [31,32], serum
vitamin E measurements were performed in a total of 19 dogs
including normal and PRA-affected Swedish vallhund dogs as well
as mixed breed colony dogs from the Retinal Disease Studies
Facility at the University of Pennsylvania School of Veterinary
Medicine. Following collection, serum samples were frozen until
analysis at the Pennsylvania Animal Diagnostic Laboratory System
Toxicology Laboratory at the University of Pennsylvania School of
Veterinary Medicine. For sample preparation, vitamin E was
extracted from the serum, filtered, and analyzed with a liquid
chromatography system equipped with fluorescence detector
(Shimadzu, Columbia, MD, USA). For quality control, serum
with certified vitamin E concentration from the National Institute
of Standards and Technology (NIST, Gaithersburg, MD, USA)
was obtained and analyzed together with each batch of our canine
serum samples. All vitamin E measurements were reported as the
concentration of the most biologically active homologue, alpha
tocopherol. A Wilcoxon rank sum test was performed to compare
the values between groups.
In an attempt to identify any environmental risk factors
contributing to the development and progression of PRA in
Swedish vallhund dogs, a short questionnaire was distributed to
dog owners and breeders. Topics of inquiry included husbandry
practices, as well as the previous occurence of any systemic or
ocular disease.
Results
Clinical Phenotype
Between June 2005 and November 2011 we examined a total of
199 Swedish vallhund dogs. In addition, we evaluated eye
examination data from certified veterinary ophthalmologists and
eye panelists provided to us by the owners of an additional 125
Swedish vallhund dogs. In total, 113 of the 324 dogs examined
exhibited a clinical phenotype consistent with Swedish vallhund
retinopathy, resulting in an estimated disease prevalence of 34.9%.
Based on all the available information, we identified a new retinal
Progressive Retinal Atrophy in the Swedish Vallhund
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disease phenotype which appears to be breed specific since we are
not aware of the presence of a similar disease phenotype in other
dog breeds. By following individual affected dogs over time
(Tables 1 and 2), we were able to define three distinct stages of
the disease based on the severity of the clinical signs. The following
phenotypic descriptions and numbers of affected dogs are based on
the clinical examinations performed by the authors (AMK and
PV) exclusively. Stage 1, the earliest stage with the mildest clinical
signs, was characterized by a diffuse multifocal red or brown
discoloration of the tapetal fundus (Fig. 2D–F). These abnormal-
ities were seen in 34 dogs with a mean age (6 standard deviation)
of 4.363.7 years, but were noted as early as 1.9 months and as late
as 17.8 years of age. There were no visible lesions in the nontapetal
fundus. Dogs in Stage 1 exhibited no clinical signs of vision loss. In
Stage 2, the retina showed signs of degeneration, indicated by
multifocal, geographic thinning, beginning in the periphery and
spreading throughout the tapetal fundus (Fig. 2G–I). A total of 25
dogs were examined and found to have Stage 2 disease. The mean
age at diagnosis was 6.263.1 years but changes were seen as early
as 1.1 and as late as 12.6 years of age. While the majority of dogs
with these degenerative changes did not appear to have vision
problems initially, some owners reported that their dogs exhibited
mild to moderate signs of night-blindness as the areas of retinal
thinning expanded. Seven dogs with a mean age of 12.262.6 years
were diagnosed with Stage 3 disease, characterized by more diffuse
retinal thinning affecting most of the tapetal fundus (Fig. 2J–L).
Stage 3-changes were observed as early as 9.2 years and as late as
15.4 years. These dogs suffered from loss of night-vision and
severely impaired day-vision; some dogs were assessed as
completely blind by their owners.
In order to better understand the rate of disease progression,
whenever possible, repeated examinations of specific dogs were
performed over the 6.5-year period of the study. Although the
precise duration that an animal spent in a particular disease stage
could not be determined based on the voluntarily nature of the
examinations and the widespread distribution of the study
population across several continents, repeated examinations were
used to provide a rough estimate of disease progression. When
looking at dogs with multiple examinations, a total of five dogs
were followed at Stage 1 for a minimum period of 0.9 years and a
maximum period of 2.3 years (mean of 1.2 years) without any signs
of progression to subsequent disease stages (Table 2). One
example of note is a dog that was repeatedly examined until the
age of 17.8 years but never progressed beyond Stage 1. A total of
four dogs were followed at Stage 2 for a minimum period of 1.8
years and a maximum period of 3.9 years (mean of 2.7 years)
without any signs of progression to subsequent disease stages. The
discrepancies noted with respect to rate of disease progression
among Swedish vallhund dogs suggest that genetic or environ-
mental disease modifiers are likely to play a role in the
pathogenesis. During the study period, a total of ten dogs showed
progression to subsequent disease stages with repeated examina-
tion (Table 1). These dogs were followed for a minimum period
of 1.1 years and a maximum period of 7.3 years (including other
ophthalmologists’ findings) with a mean of 4.0 years.
Evaluation of retinal function in 15 Swedish vallhund dogs (nine
dogs at Stage 2, two dogs at Stage 3, and four normal control dogs)
by electroretinography revealed a decrease of both rod and cone
photoreceptor-mediated function in Stages 2 and 3 (Fig. 3). While
the small sample size did not permit a detailed statistical analysis,
our recordings indicate that relative cone function may be lost at a
slower rate than rod function; this would be consistent with the
dog owners’ observations that night-blindness precedes loss of day-
vision at Stage 3.
Unrelated to the herein described phenotype specific to Swedish
vallhund retinopathy, we also observed focal and multifocal
inactive chorioretinal scars in a number of dogs (n = 14). These
lesions were characterized by focal areas of pigmentation that were
often surrounded by a hyperreflective halo due to retinal thinning
(Fig. S1). These ‘bull’s eye’ lesions are most consistent with
multifocal acquired chorioretinopathy (MAC), a disorder previ-
ously reported in herding and working dogs [33–36]. According to
information provided by the dog owners, at least some of the
Swedish vallhund dogs with MAC-like lesions suffered from severe
gastrointestinal parasitism early in life which may have resulted in
multifocal chorioretinitis. In three Swedish vallhund dogs we
found these MAC lesions combined with the breed-specific
retinopathy. Two Swedish vallhund dogs that were not examined
by the authors were diagnosed with retinal folds (n = 2, 0.85% of
all examinations), a mild form of retinal dysplasia.
Histologic Phenotype
Because our study involved only privately owned dogs and no
purpose-bred research animals, the availability of tissue samples
for histologic examination was limited to eight eyes generously
donated by owners. As such, these samples were typically obtained
from older dogs that died of causes unrelated to the retinopathy.
The retinal disease status was not always known at the time of
death and tissue collection. Despite these limitations, the available
tissues still provided valuable information about changes in retinal
architecture in advanced disease which may contribute to a better
understanding of the etiopathogenesis. Most valuable was the
tissue sample from a 15-year old Stage-3 retina with distinct
regions of varying disease severity (Fig. 4B): Small islands of
relatively normal appearing retina (Fig. 4B1) were surrounded by
large areas of advanced retinal degeneration with loss of both rod
and cone photoreceptors (Fig. 4B2). Regions with ‘end-stage’
disease showed severe retinal thinning with complete loss of
normal architecture (Fig. 4B3). The transition between mildly
and severely degenerated retinal regions was at times abrupt
(Fig. 4C). The loss of photoreceptors was associated with the
accumulation of autofluorescent material in the subretinal space
and within the RPE (Fig. 4C–D). The presence of this material
was more excessive than would be seen with other forms of PRA
(e.g., prcd shown in Fig. 4E) or normal aging (Fig. 4F). We posit
that this acid-fast positive, ceroid/lipofuscin-like material was
likely the source of the red or brown discoloration clinically seen in
the tapetal fundus and defining Stage 1 of the disease. However,
based on the available data, the presence of autofluorescent
material does not provide us with specific clues about the cellular
and molecular disease mechanisms resulting in photoreceptor loss
and retinal degeneration. We suspect that the disease-related
increase in autofluorescence may be able to be visualized in the
living animal when proper imaging tools are used. As such, this
will be one of our future goals.
Pedigree and Candidate Gene Analysis
Pedigree analysis of nearly 300 Swedish vallhund dogs,
including 125 affected animals, indicates a clear genetic contribu-
tion (Fig. 5). While variability in the age of disease onset and
incomplete pedigree information preclude us from drawing any
definitive conclusions about the mode of inheritance, the available
data is most consistent with an autosomal recessive pattern. This
notion is supported by the lack of a sex predisposition, and the
observation that affected animals can originate from the breeding
of non-affected dogs.
In order to perform candidate gene screening, we collected
blood samples from normal and affected Swedish vallhund dogs.
Progressive Retinal Atrophy in the Swedish Vallhund
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Seven known canine PRA genes were tested for possible
association: BEST1 [8,9], PDE6B and PDE6A [23–26], PRCD
[27], RPE65 [6,7], NPHP4 [28], and CNGB3 [29,30]. Flanking
microsatellite markers were selected for each locus and tested in
case and control pools for possible allelic differences. No PCR
completion was detected in any of the pools. The affected dogs did
not share common alleles in any loci of six candidate genes,
excluding them as causative for the disease (Table S3). As both
PRCD markers were monomorphic and uninformative, no
conclusions could be drawn about a possible involvement of this
gene in the disease process.
Evaluation of Serum Vitamin E Concentrations and Other
Potential Risk Factors
Because the fundic appearance in early stages of the Swedish
vallhund retinopathy is reminiscent of vitamin E deficiency
retinopathy [31,32,37], blood was collected and vitamin E (alpha
tocopherol) levels were determined in three retinopathy-affected
and six normal control Swedish vallhund dogs and compared to
ten normal mixed-bred dogs housed in a well-controlled research
colony. Overall, the serum vitamin E concentrations were lower in
the Swedish vallhund dogs (18.8–44.5 mg/mL, median: 28 mg/
mL) compared to the normal mixed-bred colony dogs (36.2–
48.8 mg/mL, median: 40.7 mg/mL; p= 0.01, Wilcoxon rank sum
test), but well within the previously described normal range for this
species [31,32,37]. Except for one individual, the measurements of
the affected animals (18.8, 22.9, and 26.2 mg/mL) fell within the
range of the normal Swedish vallhund dogs (19–44.5 mg/mL;
median: 29 mg/mL), making vitamin E deficiency an unlikely
etiology for Swedish vallhund retinopathy.
Discussion
Based on its inheritance patterns and the progressive nature of
vision loss, the novel retinopathy observed in Swedish vallhund
dogs appears to be a form of PRA. The phenotype of this disease is
rather different from most known forms of PRA, with a multifocal
rather than diffuse distribution of retinal degeneration. Further-
more, age of disease onset and rate of disease progression can vary
considerably, even in closely related animals. Based on our
observations gathered during ophthalmic examination of affected
dogs, we propose three clinical stages of disease ranging from
diffuse multifocal red/brown discoloration of the tapetal fundus
without associated visual deficits (Stage 1), to geographic retinal
thinning/degeneration with mild to moderate signs of night-
blindness (Stage 2), to more diffuse retinal thinning/degeneration
affecting most of the tapetal fundus and associated with night-
vision loss and severely impaired day-vision (Stage 3). Paired with
these clinical observations, functional and histologic examination
of diseased retinas confirmed that this is a progressive retinopathy
Table 1. Swedish vallhund dogs that showed progression with repeated examination.
Vallhund ID Age at Stage 1 diagnosis (years) Age at Stage 2 diagnosis (years) Age at Stage 3 diagnosis (years)
CSC 2.2 3.4 _
GRP 3.9 4.9, 6.9, 9.1 _
LHU 0.6 2.0 _
PCC 1.5 3.7 _
GBB 3.9 4.9, 6.9, 9.1 _
FEE _ 9.6 13.4
FJJ _ 8.6, 8.7, 9.2 15.3
FY _ 4.6 8.3
JMM _ 11.4, 12.0 14.5
FL _ 5.3 12.6
At the authors’ discretion, selected examinations performed by other certified veterinary ophthalmologists were included in the data analysis in order to provide a more
complete picture of disease progression.
doi:10.1371/journal.pone.0106610.t001
Table 2. Swedish vallhund dogs that showed no progression to subsequent disease stages with repeated examination.
Vallhund ID Age at Stage 1 diagnosis (years) Age at Stage 2 diagnosis (years) Age at Stage 3 diagnosis (years)
FHL 0.8, 1.8 _ _
JLG 16.9, 17.4, 17.8 _ _
JM 10.4, 11.4 _ _
KCY 5.2, 7.4 _ _
WAG 1.9, 2.9 _ _
CTG _ 8.7, 11.5, 12.6 _
HMAY _ 4.9, 7.1 _
KKB _ 1.1, 4.1 _
VM _ 2.2, 4.0 _
doi:10.1371/journal.pone.0106610.t002
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Figure 3. Standard electroretinograms (ERGs) recorded from normal and affected Swedish vallhund dogs. Compared to the ERG
recordings of a normal dog (top row) both rod- and cone-mediated retinal functions are clearly reduced at Stage 2. ERG amplitudes are further
decreased at Stage 3 (third row), especially rod-mediated responses, and may not even be recordable in some affected dogs (flat lines in fourth row).
doi:10.1371/journal.pone.0106610.g003
Figure 2. Clinical appearance of the ocular fundi of normal and affected Swedish vallhund dogs. (A–C) Normal appearance of the ocular
fundus with the colored tapetum lucidum (responsible for eye shine), the well developed retinal vasculature, and the optic nerve head (arrows). It is
not unusual to see a thin halo of altered reflectivity or conus papillaris around the optic nerve head as seen in B and C. (D–F) Stage 1 is characterized
by multifocal red or brown discoloration of the tapetal fundus (arrows). (G–I) In Stage 2, the retina showed signs of degeneration, indicated by
multifocal, geographic thinning (arrow heads), beginning in the periphery and spreading throughout the tapetal fundus. (J–L) Stage 3 is defined by a
more diffuse retinal thinning recognized by the large, bright (hyperreflective) regions affecting most of the tapetal fundus (arrow heads). The conus
papillaris also appears wider in Stage 3 (arrows).
doi:10.1371/journal.pone.0106610.g002
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affects both rod and cone photoreceptors as well as the RPE. One
of the most unique features of this disease is the excessive
accumulation of autofluorescent material within the RPE, which
may be the source of the initial discoloration noted within the
tapetal fundus.
Our work to characterize this new canine retinopathy draws
from well established collaborations between clinicians, geneticists,
and dog breeders. Such an international effort was crucial
considering that Swedish vallhund dogs are much fewer in
numbers compared to other, more popular breeds. Our pedigree
analysis included Swedish vallhund dogs examined in seven
different countries, spanning three continents, and was highly
suggestive of a genetic etiology and an autosomal recessive mode
of inheritance. Because the affected dogs did not share common
alleles, we excluded single, fully penetrant mutations in six known
canine retinal disease genes: BEST1 [8,9], PDE6B and PDE6A
[23–26], RPE65 [6,7], NPHP4 [28], and CNGB3 [29,30].
However, dominant or incompletely penetrant mutations in any of
these genes cannot be formally ruled out. Overall, the candiate
gene analysis suggests that the Swedish vallhund retinopathy is
genetically distinct from other forms of PRA, and our ongoing
genome-wide studies have identified a new, unreported PRA locus
in this breed (Ahonen et al., unpublished data).
The most striking feature of Swedish vallhund PRA/retinopa-
thy is the individual variability in disease progression, even among
related dogs and those raised in similar environments. While some
of the affected dogs progressed to subsequent stages of disease with
repeated examination, others did not progress beyond early stages
despite advanced age. This is reminiscent of canine cone-rod
dystrophy 1 (cord1-PRA, suspected RPGRIP1 mutation) in the
miniature long-haired dachshund, where genotype-phenotype
discordance has been demonstrated within a genetically isolated
population due to the presence of genetic disease modifiers [38].
Variability in disease phenotype caused by a particular mutation,
either within one breed (e.g., X-linked PRA1) [39] or between
multiple breeds (e.g., prcd) [40] has also been described in other
types of PRA. Genetic disease modifiers that influence the severity
of the disease phenotype also exist for other canine genetic
Figure 4. Histologic changes associated with Swedish vallhund retinopathy. (A) High quality section through a wildtype canine retina
shows the normal retinal layers and architecture. (B) Different regions of the same 15-year old Swedish vallhund retina with Stage 3 disease. Small
islands of relatively normal appearing retina (B1) are surrounded by severely degenerated retina characterized by the loss of photoreceptors and ONL
thinning (B2). Retinal architecture is completely lost with end-stage disease and severe retinal degeneration (B3). (C) At the transition between
relatively well preserved and completely absent (*) retinal architecture, loss of photoreceptors (cones are labeled red with hCAR antibody) is
associated with accumulation of autofluorescent material (green) in the subretinal space and within the RPE (arrows). (D) Accumulation of
autofluorescent material (green) within the RPE can also be seen in a well preserved region of a 13-year old Stage-2 affected retina (arrow), possibly
indicating that increased autofluorescence may precede loss of photoreceptors. Accumulation of autofluorescent material within the RPE (arrows)
can also be seen with other forms of PRA (E, prcd) or with normal aging (F, 11-year old normal canine retina) but to a much lesser extent than in
affected Swedish vallhund dogs. Staining: H&E (A and B) and fluorescent immunolabeling (C–F). Cell nuclei are shown in blue with DAPI (C–F); hCAR,
human cone arrestin; AF, autofluorescence. Calibration bars: 20 mm. Layers of the retina: RPE, retinal pigment epithelium; PR, photoreceptors; ONL,
outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer; NFL, nerve fiber layer.
doi:10.1371/journal.pone.0106610.g004
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disorders, such as Collie eye anomaly [41]. We suspect that genetic
modifiers may be responsible for the variation in disease
phenotype of PRA-affected Swedish vallhund dogs; as such, this
will be a major focus of our future investigations.
Environmental disease modifiers may also play a role in
determining onset and progression of PRA in the Swedish
vallhund dogs. A classic example is the effect of light exposure
on the progression of retinal degeneration in English mastiff dogs
with autosomal dominant PRA [17]. Our attempt to identify
environmental factors which may affect disease progression by
questioning dog owners proved inconclusive. The observation of
red/brown fundus changes at Stage 1 and the accumulation of
autofluorescent lipofuscin-like material within the RPE was
remotely reminiscent of vitamin E deficiency retinopathy
[31,32,37]. However, normal serum vitamin E (alpha-tocopherol)
concentrations in a few affected Swedish vallhund dogs failed to
support such a connection.
We posit that the accumulation of autofluorescent, lipofuscin-
like material corresponds to the red/brown discoloration clinically
seen in the tapetal fundus, and may precede the loss of
photoreceptors. Future investigations using specialized, high-
resolution in vivo imaging tools, such as optical coherence
tomography and scanning laser ophthalmoscopy, will permit a
much more detailed investigation into the source of the
autofluorescence. Because this material appears to be more
abundant in affected Swedish vallhund dogs compared to other
forms of PRA with primary photoreceptor death or compared to
the normal aging canine retinas, we suspect that the autofluor-
escent material is intimately associated with the disease-causing
gene mutation. However, based on our available data, we are
unable to conclude whether the Swedish vallhund disease
primarily affects the RPE or the photoreceptors; both options
are possible [42]. Pathologic accumulation of lipofuscin in the
RPE is also a feature of several human diseases, including fundus
flavimaculatus (Stargardt’s disease) [43], but at this point it
remains unclear which human condition is most closely modeled
by Swedish vallhund PRA.
In summary, we describe a unique form of PRA in the Swedish
vallhund dog. The novelty of this disease is not only based on the
retinal disease phenotype, but also the variation in age of onset and
rate of disease progression. An autosomal-recessive mode of
inheritance appears most likely and mutations in several known
retinal disease genes have been excluded. Genetic and/or
environmental disease modifiers likely contribute to the disease
Figure 5. Large Swedish vallhund pedigree. This pedigree is composed of nearly 300 dogs, including 125 animals affected with the breed-
specific retinopathy. Affected dogs listed in Tables 1 and 2 are highlighted in yellow and green, respectively. Squares, males; circles, females; white
symbols, unaffected; black symbols, retinopathy affected.
doi:10.1371/journal.pone.0106610.g005
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phenotype, but hypovitaminosis E was excluded as a contributing
factor.
Supporting Information
Figure S1 Multifocal acquired chorioretinopathy (MAC)
in a Swedish vallhund dog. The multifocal black spots in the
tapetal fundus represent post-inflammatory scars. With a classic
‘bull’s eye’ lesion, the larger black pigmented spot is surrounded by
a bright, yellow zone or halo, a sign of severe, focal retinal
thinning/degeneration.
(TIF)
Table S1 Primary antibodies used for immunohistochemistry.
(DOCX)
Table S2 Primers used to amplify microsatellite markers.
(XLSX)
Table S3 Association analysis of six known canine PRA genes in
Swedish vallhund retinopathy. Eleven cases and eleven controls
were pooled and genotyped for one to four microsatellite markers
in each locus. The fragment sizes (bp) are marked in the table. The
fact that the affected dogs do not share common alleles in any loci
and same alleles were present in both cases and controls excludes
these known PRA genes as candidates. For the CNGB3_29_35.82
and BEST1_18_57.49 markers, the pooled samples were
individually genotyped to confirm the results. The NPHP4
markers were genotyped separately in a different set of dogs.
(XLSX)
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